MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition
Journal of Experimental Medicine · 2023
DOI: 10.1084/jem.20221524 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2023. Verfasst von Mark R Silvis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Huntsman Cancer Institute, University of Utah , Salt Lake City, UT, USA. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, University of Utah, National Cancer Institute.
Abstract (Originalsprache)
Pharmacological inhibition of KRAS>RAF>MEK1/2>ERK1/2 signaling has provided no clinical benefit to patients with pancreatic ductal adenocarcinoma (PDAC). Interestingly, combined inhibition of MEK1/2 (with trametinib [T]) plus autophagy (with chloroquine [CQ] or hydroxychloroquine [HCQ]) demonstrated striking anti-tumor effects in preclinical models and in a patient (Patient 1). However, not all patients respond to the T/HCQ regimen, and Patient 1 eventually developed resistant disease. Here we report that primary or acquired resistance is associated with focal DNA copy number gains encompassing c-MYC. Furthermore, ectopic expression of c-MYC in PDAC cell lines rendered them T/HCQ resistant. Interestingly, a CDK4/6 inhibitor, palbociclib (P), also induced autophagy and overrode c-MYC–mediated T/HCQ resistance, such that P/HCQ promoted regression of T/HCQ-resistant PDAC tumors with elevated c-MYC expression. Finally, P/HCQ treatment of Patient 1 resulted in a biochemical disease response. These data suggest that elevated c-MYC expression is both a marker and a mediator of T/HCQ resistance, which may be overcome by the use of P/HCQ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Huntsman Cancer Institute, University of Utah , Salt Lake City, UT, USA.
- Department of Oncological Sciences, University of Utah , Salt Lake City, UT, USA.
- ARUP Laboratories , Salt Lake City, UT, USA.
- Intermountain Medical Center , Murray, UT, USA.
- Department of Radiology, University of Utah , Salt Lake City, UT, USA.
- Department of Pathology, University of Utah , Salt Lake City, UT, USA.
ORCID-Profile: Mark R Silvis, Dilru Silva, Riley Rohweder, Sophia Schuman, Swapna Gudipaty, Amanda Truong, Jeffrey Yap, Kajsa Affolter, Martin McMahon, Conan Kinsey
Förderung
- NCI NIH HHS
- University of Utah
- National Cancer Institute
- HCI Preclinical Research Shared Resource
- Lustgarten Foundation
- Huntsman Cancer Foundation
- Huntsman GI Disease Center
- Pfizer Consumer Healthcare
Zitieren
APA
Silvis, M. R., Silva, D., Rohweder, R., Schuman, S., Gudipaty, S., Truong, A., Yap, J., Affolter, K., McMahon, M., & Kinsey, C. (2023). MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20221524
Vancouver
Silvis MR, Silva D, Rohweder R, Schuman S, Gudipaty S, Truong A, et al. MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition. Journal of Experimental Medicine. 2023. doi:10.1084/jem.20221524
BibTeX
@article{Silvis2023,
author = {Silvis, Mark R and Silva, Dilru and Rohweder, Riley and Schuman, Sophia and Gudipaty, Swapna and Truong, Amanda and Yap, Jeffrey and Affolter, Kajsa and McMahon, Martin and Kinsey, Conan},
title = {MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition},
journal = {Journal of Experimental Medicine},
year = {2023},
doi = {10.1084/jem.20221524}
}
EUVIMED